Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V 1A and V 2 receptor antagonist, in dogs with pacing-induced congestive heart failure

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Kusayama T.   Tsukada J.   Tokioka T.   Uchida W.   Inagaki O.   Iizumi Y.   Tanaka A.   Honda K.  

European Journal of Pharmacology, Vol. 376, Iss. 3, 1999-07 ,pp. : 239-246

Elsevier

Access to resources Recommend Favorite

In vivo and in vitro characterisation of a nonpeptide vasopressin V 1A and V 2 receptor antagonist (YM087) in the rat

By Risvanis J.   Naitoh M.   Johnston C.I.   Burrell L.M.  

European Journal of Pharmacology, Vol. 381, Iss. 1, 1999-09 ,pp. : 23-30

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V 1A and V 2 receptor antagonist, in dogs

By Yatsu T.   Tomura Y.   Tahara A.   Wada K.-i.   Tsukada J.   Uchida W.   Tanaka A.   Takenaka T.  

European Journal of Pharmacology, Vol. 321, Iss. 2, 1997-02 ,pp. : 225-230

Elsevier

Access to resources Recommend Favorite

Intravenous Conivaptan

By Moen Marit D.   Keating Gillian M.  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 5, 2008-01 ,pp. : 341-348

Adis International

Access to resources Recommend Favorite

Conivaptan effective in hyponatraemia

By  

Inpharma, Vol. 1, Iss. 1464, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite